Cirrhosis News and Research RSS Feed - Cirrhosis News and Research

Cirrhosis is a condition in which the liver slowly deteriorates and malfunctions due to chronic injury. Scar tissue replaces healthy liver tissue, partially blocking the flow of blood through the liver. Scarring also impairs the liver’s ability to control infections, remove bacteria and toxins from the blood, process nutrients, hormones and drugs, make proteins that regulate blood clotting and produce bile to help absorb fats—including cholesterol—and fat-soluble vitamins.
Researchers identify new virus that plays role in rare type of liver cancer

Researchers identify new virus that plays role in rare type of liver cancer

More than a cause of a simple infection, viruses are often involved in the development of serious diseases. Such is the case with liver cancer, which often develops in an organ that has been weakened by hepatitis B or C virus. [More]
Yale study identifies new barrier to caring for chronic hepatitis C patients

Yale study identifies new barrier to caring for chronic hepatitis C patients

Nearly one in four patients with chronic hepatitis C (HCV) are denied initial approval for a drug therapy that treats the most common strain of the infection, according to a Yale School of Medicine study. [More]
Multi-national group of scientists developing new test for Hepatocellular Carcinoma

Multi-national group of scientists developing new test for Hepatocellular Carcinoma

A group of clinicians and geochemists are working to develop a test for the most common form of primary liver cancer, HCC (Hepatocellular Carcinoma). HCC kills over 600,000 people worldwide every year. [More]
Advanced liver damage in hepatitis C patients grossly underestimated and underdiagnosed

Advanced liver damage in hepatitis C patients grossly underestimated and underdiagnosed

The number of hepatitis C patients suffering from advanced liver damage may be grossly underestimated and underdiagnosed, according to a study led by researchers at Henry Ford Health System and the U.S. Centers for Disease Control and Prevention. [More]
UC San Diego researchers discover cells that regenerate better liver tissue than ordinary liver cells

UC San Diego researchers discover cells that regenerate better liver tissue than ordinary liver cells

The mechanisms that allow the liver to repair and regenerate itself have long been a matter of debate. Now researchers at University of California, San Diego School of Medicine have discovered a population of liver cells that are better at regenerating liver tissue than ordinary liver cells, or hepatocytes. [More]
Breath analysis shows potential biomarkers for early-stage diagnosis of liver disease

Breath analysis shows potential biomarkers for early-stage diagnosis of liver disease

A natural compound called limonene, which is found in oranges and lemons, could be indicative in early-stage diagnosis of liver disease, according to research published in the journal EBioMedicine by researchers in the Molecular Physics Group at the University of Birmingham. [More]
IQWiG examines added benefit of dasabuvir and ombitasvir/paritaprevir/ritonavir in different patient groups

IQWiG examines added benefit of dasabuvir and ombitasvir/paritaprevir/ritonavir in different patient groups

Dasabuvir (trade name Exviera) and the fixed-dose drug combination ombitasvir/paritaprevir/ritonavir (trade name Viekirax) have been available since January 2015 for the treatment of adults with chronic hepatitis C infection. The German Institute for Quality and Efficiency in Health Care had examined their added benefit in a dossier assessment completed in April 2015. [More]
Study demonstrates significance of EMT as potential therapeutic target for reversing kidney disease

Study demonstrates significance of EMT as potential therapeutic target for reversing kidney disease

Adults who are worried or terrified sometimes curl up into a fetal position. Likewise, adult cells that are injured, including genetic injury leading to cancer, initiate a process that was present during embryonic development. [More]
Exalenz Bioscience, Galectin Therapeutics to use BreathID test to assess GR-MD-O2 efficacy in NASH Cirrhosis patients

Exalenz Bioscience, Galectin Therapeutics to use BreathID test to assess GR-MD-O2 efficacy in NASH Cirrhosis patients

Exalenz Bioscience, a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced a collaboration with Galectin Therapeutics to use the BreathID test to monitor patients in a Phase II study evaluating GR-MD-02. [More]
Weight loss through lifestyle modifications, bariatric surgery can reduce features of NASH

Weight loss through lifestyle modifications, bariatric surgery can reduce features of NASH

Weight loss through both lifestyle modification and bariatric surgery can significantly reduce features of nonalcoholic steatohepatitis (NASH), a disease characterized by fat in the liver, according to two new studies published in Gastroenterology, the official journal of the American Gastroenterological Association. [More]
Resistance training can help reduce liver fat levels in patients suffering from fatty liver disease

Resistance training can help reduce liver fat levels in patients suffering from fatty liver disease

Resistance training in the gym leads to a fall in liver fat levels. This is the finding of a new study held at the University of Haifa in cooperation with Tel Aviv Medical Center and Tel Aviv University. [More]
NuSI launches groundbreaking clinical study to halt nonalcoholic fatty liver disease in children

NuSI launches groundbreaking clinical study to halt nonalcoholic fatty liver disease in children

Nutrition Science Initiative has launched the first-ever randomized, controlled clinical trial to determine whether removing added sugars from the diet can halt or even reverse nonalcoholic fatty liver disease (NAFLD) in children. [More]
Diabetes drug metformin can also treat portal hypertension

Diabetes drug metformin can also treat portal hypertension

The diabetes drug metformin continues to expand beyond its treatment for type 2 diabetes. In addition to its potential use in treating age-related health problems, metformin can treat portal hypertension—high blood pressure in the liver resulting from cirrhosis, according to a new study in American Journal of Physiology—Gastrointestinal and Liver Physiology. [More]
dlDNA marks progression of HBV-related liver disease

dlDNA marks progression of HBV-related liver disease

The level of serum duplex-linear DNA increases markedly with liver disease progression and development of hepatocellular carcinoma in patients with chronic hepatitis B virus (HBV) infection, suggests research published in Gut. [More]

Hiroshima University researchers develop accurate method to detect drug resistant HCV mutation

A rapid, sensitive, and accurate method to detect drug resistant hepatitis C virus (HCV) mutants has been developed. Researchers at Hiroshima University established a system to rapidly and accurately measure the presence of HCV Y93H drug resistant mutant strains, and evaluate the proportion of patients harboring this mutation prior to treatment. [More]
AASLD creates online Recommendations for Testing, Managing, and Treating Hepatitis C

AASLD creates online Recommendations for Testing, Managing, and Treating Hepatitis C

The American Association for the Study of Liver Diseases, in partnership with the Infectious Diseases Society of America and in collaboration with the International Antiviral Society-USA, created online Recommendations for Testing, Managing, and Treating Hepatitis C in 2014 to aid practitioners treating patients infected with hepatitis C virus (HCV). [More]
The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Eli Lilly and Company announced that The Lancet Oncology has published results of the Phase III REACH trial that evaluated CYRAMZA (ramucirumab) as a second-line treatment for people with hepatocellular carcinoma (HCC), also known as liver cancer. While the REACH trial's primary endpoint of overall survival favored the CYRAMZA arm, it was not statistically significant. [More]
New book examines all aspects of HBV and HDV infections

New book examines all aspects of HBV and HDV infections

Despite the availability of an effective vaccine for hepatitis B, hundreds of millions of people worldwide are infected with the hepatitis B virus (HBV). This virus can cause serious liver damage and cancer in chronically infected patients. Hepatitis delta virus (HDV), a satellite of HBV, can exacerbate the disease. [More]
Tioga Pharmaceuticals announces commencement of asimadoline Phase 2 study for treatment of pruritus

Tioga Pharmaceuticals announces commencement of asimadoline Phase 2 study for treatment of pruritus

Tioga Pharmaceuticals, a clinical stage biotechnology company, today announced the initiation of a Phase 2 clinical study of asimadoline, a novel, well-studied kappa-opioid receptor specific agonist, for the treatment of pruritus or itching. The double-blind, placebo-controlled clinical study is designed to evaluate the safety, tolerability, and clinical efficacy of asimadoline in patients with pruritus due to atopic dermatitis and is being conducted at 20 clinical study centers in the United States. [More]
GSU scientists design new MRI technique for early detection of liver tumors

GSU scientists design new MRI technique for early detection of liver tumors

Scientists at Georgia State University with funding from the National Institute of Biomedical Imaging and Bioengineering have designed an imaging technique to detect early-stage liver tumors, and have proven it successful in mice. [More]
Advertisement
Advertisement